Novo Nordisk says women lost 25% of weight on Cagrisema in trial subgroup

The figure comes from a post hoc analysis of the Redefine 1 trial, not the trial's overall result.

Novo Nordisk said a post hoc analysis of its Redefine 1 trial found that women taking investigational Cagrisema 2.4mg/2.4mg lost an average of 25% of their body weight.

That figure sits above the trial's headline numbers. In a 6-K filing with the SEC, Novo Nordisk reported that under the treatment policy estimand, which counts all participants regardless of whether they stayed on the drug, Redefine 1's overall average weight loss was 20.4%. Among those who adhered to treatment throughout the 68 weeks, the figure was 22.7%, against 2.3% for placebo, the filing said.

Novo Nordisk had been aiming for a 25% weight-loss result across the full trial population, a target the overall data fell short of, according to Pharmaceutical Executive, which reported that only about half of participants reached the highest dose within the trial's timeframe. Cagrisema has not yet been approved by the FDA. Novo Nordisk filed for approval in late 2025 or early 2026, with a decision reportedly expected later this year, healnourishgrow.com reported, citing the company's regulatory timeline.

The new women's subgroup number gives Novo Nordisk a result it can set against Eli Lilly's 20.2% headline figure for Zepbound from the broader Redefine population comparison. But it comes from a post hoc analysis rather than a prespecified head-to-head trial, a distinction that has mattered before: cardiovascular data presented at the EASD meeting did little to shift the narrative around Novo Nordisk's loss of market share to Lilly. Framing Cagrisema's results around a specific group of patients rather than the trial population as a whole may help the company's pitch to doctors and insurers, even if it does not change the broader competitive picture against tirzepatide.